FEMY Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.200

Open

4.200

VWAP

3.97

Vol

21.27K

Mkt Cap

11.69M

Low

3.840

Amount

84.44K

EV/EBITDA(TTM)

--

Total Shares

3.02M

EV

10.27M

EV/OCF(TTM)

--

P/S(TTM)

4.53

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

Show More

Events Timeline

(ET)

2026-05-13

09:10:00

Femasys Receives CE Mark Approval for FemHSG Catheter

2026-04-16 (ET)

2026-04-16

09:20:00

Femasys Partners with AMI Technologies for Fertility Portfolio in Israel

2026-03-18 (ET)

2026-03-18

09:10:00

Femasys Appoints Kenneth D. Eichenbaum to Board of Directors

2026-03-10 (ET)

2026-03-10

09:20:00

Femasys Initiates Patient Enrollment in FINALE Clinical Trial

2026-02-26 (ET)

2026-02-26

09:10:00

Femasys FemBloc System Achieves MDSAP Certification

2026-02-23 (ET)

2026-02-23

09:10:00

Femasys Receives AMA Approval for New CPT Code

News

NASDAQ.COM

06-25NASDAQ.COM

Femasys Regains Compliance with Nasdaq Listing Requirements

seekingalpha

06-24seekingalpha

Femasys Regains Nasdaq Compliance, Focuses on Strategic Growth

Newsfilter

06-24Newsfilter

Femasys Regains Nasdaq Compliance Status

seekingalpha

04-01seekingalpha

Femasys Appoints New COO John Canning to Drive Operations

seekingalpha

03-31seekingalpha

Femasys Reports FY Loss with Revenue of $2.29M

Newsfilter

02-27Newsfilter

Femasys Grants Stock Options to New Employees

2 Analyst Rating

Wall Street analysts forecast FEMY stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

4.75

High

6.50

Current: 0.000

Low

3.00

Averages

4.75

High

6.50

Lake Street

Ben Haynor

Buy

initiated

$1.50

AI Analysis

2026-03-03

Reason

Lake Street

Ben Haynor

Price Target

$1.50

AI Analysis

2026-03-03

initiated

Buy

Reason

Lake Street analyst Ben Haynor initiated coverage of Femasys with a Buy rating and $1.50 price target. FemBloc is the first and only non-surgical alternative that can be performed in an OB/GYN office without incisions, anesthesia, or permanent implants and the device has CE Mark clearance and is currently in a registration trial for PMA approval from the FDA, notes the analyst. The latest data suggests about 1.2M surgical sterilizations occur in the U.S. each year, so this could be "a multi-billion-dollar market for Femasys in the U.S. alone," depending on average selling prices, the analyst tells investors.

Laidlaw

Yale Jen

initiated

$6.50

2025-11-20

Reason

Laidlaw

Yale Jen

Price Target

$6.50

2025-11-20

initiated

Reason

Laidlaw analyst Yale Jen initiated coverage of Femasys with a Buy rating and $6.50 price target. Femasys is a development stage medical technology company focusing on two lead women healthcare products, FemaSeed and FemBloc, the analyst tells investors in a research note. The firm says FemaSeed is exploring a new and large market opportunity via gynecologist channel while FemBloc is heading to pivotal clinical study backed by "robust" prior clinical data.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FEMY

Unlock Now

Valuation Metrics

The current forward P/E ratio for Femasys Inc (FEMY.O) is 0.00, compared to its 5-year average forward P/E of -2.10. For a more detailed relative valuation and DCF analysis to assess Femasys Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.10

Current PE

0.00

Overvalued PE

-0.72

Undervalued PE

-3.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.05

Current EV/EBITDA

-0.12

Overvalued EV/EBITDA

0.11

Undervalued EV/EBITDA

-0.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

12.62

Current PS

1.23

Overvalued PS

29.21

Undervalued PS

-3.97

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks to buy below 1 $ now

Intellectia · 8 candidates

Market Cap: <= 2.00BPrice: <= $1.00Analyst Consensus: Moderate Buy, Strong BuyBeta: LowRisk, ModerateRiskWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Strive Inc

1.11B

TRX Gold Corp

271.29M

BRC Inc

247.13M

Mereo BioPharma Group PLC

84.34M

Ocean Power Technologies Inc

77.96M

Plus Therapeutics Inc

52.05M

Whales Holding FEMY

Trading Trends

People Also Watch

Frequently Asked Questions

What is Femasys Inc (FEMY) stock price today?

The current price of FEMY is 3.87 USD — it has decreased -5.15

What is Femasys Inc (FEMY)'s business?

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

What is the price predicton of FEMY Stock?

Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is4.75 USD with a low forecast of 3.00 USD and a high forecast of 6.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Femasys Inc (FEMY)'s revenue for the last quarter?

Femasys Inc revenue for the last quarter amounts to 424.89K USD, increased 24.50

What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?

Femasys Inc. EPS for the last quarter amounts to 0.22 USD, decreased -104.69

How many employees does Femasys Inc (FEMY). have?

Femasys Inc (FEMY) has 51 emplpoyees as of July 08 2026.

What is Femasys Inc (FEMY) market cap?

Today FEMY has the market capitalization of 11.69M USD.